Voted the "most admired" corporation in America by 8,000 executives, outside board members and financial analysts participating in Fortune magazine's annual survey dated Jan. 29. The honor marks the fourth straight year that Merck has ranked at top of survey.
You may also be interested in...
Cilta-cel maintained high response rates in longer-term multiple myeloma data, but ide-cel causes less cytokine release syndrome and severe neurotoxicity – and it has a March decision date at the US FDA.
Our updated graphic tracker of key developments from the leading vaccine candidates.
Pathway open for drug as post-covalent BTK option as Loxo gears up for "risky" Phase III head-to-head study in Q1 2021.